Shi Hongwei, Duan Lian, Tong Li, Pu Peng, Wei Lai, Wang Linlin, Hu Desheng, Tang Heng
Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China.
Department of Oncology, Renmin Hospital of Wuhan University, 430064 Wuhan, Hubei, China.
Rev Cardiovasc Med. 2024 Feb 27;25(3):74. doi: 10.31083/j.rcm2503074. eCollection 2024 Mar.
The development of anti-tumor drugs has notably enhanced the survival rates and quality of life for patients with malignant tumors. However, the side effects of these drugs, especially cardiotoxicity, significantly limit their clinical application. The cardiotoxicity associated with anti-tumor drugs has been a subject of extensive attention and research. Traditional to mitigate these side effects have included reducing drug dosages, shortening treatment duration, modifying administration methods, and opting for drugs with lower toxicity. However, either approach may potentially compromise the anti-tumor efficacy of the medications. Therefore, exploring other effective methods for anti-cardiotoxicity will be the focus of future research. The potential of traditional Chinese medicine (TCM) in managing cardiovascular diseases and cancer treatment has gained widespread recognition. TCM is valued for its minimal side effects, affordability, and accessibility, offering promising avenues in the prevention and treatment of cardiotoxicity caused by anti-tumor drugs. Among its constituents, flavonoids, which are present in many TCMs, are particularly notable. These monomeric compounds with distinct structural components have been shown to possess both cardiovascular protective properties and anti-tumor capabilities. In this discussion, we will delve into the classification of anti-tumor drugs and explore the underlying mechanisms of their associated cardiotoxicity. Additionally, we will examine flavonoids found in TCM and investigate their mechanisms of cardiovascular protection. This will include an analysis of how these natural compounds can mitigate the cardiac side effects of anti-tumor therapies while potentially enhancing overall patient health and treatment outcomes.
抗肿瘤药物的发展显著提高了恶性肿瘤患者的生存率和生活质量。然而,这些药物的副作用,尤其是心脏毒性,严重限制了它们的临床应用。与抗肿瘤药物相关的心脏毒性一直是广泛关注和研究的课题。减轻这些副作用的传统方法包括减少药物剂量、缩短治疗时间、改变给药方式以及选择毒性较低的药物。然而,这些方法都可能会削弱药物的抗肿瘤疗效。因此,探索其他有效的抗心脏毒性方法将是未来研究的重点。中药在治疗心血管疾病和癌症方面的潜力已得到广泛认可。中药因其副作用小、价格低廉且易于获取而受到重视,为预防和治疗抗肿瘤药物引起的心脏毒性提供了有前景的途径。在其成分中,许多中药中含有的黄酮类化合物尤为显著。这些具有独特结构成分的单体化合物已被证明具有心血管保护特性和抗肿瘤能力。在本次讨论中,我们将深入探讨抗肿瘤药物的分类,并探究其相关心脏毒性的潜在机制。此外,我们将研究中药中的黄酮类化合物,并探讨它们的心血管保护机制。这将包括分析这些天然化合物如何减轻抗肿瘤治疗的心脏副作用,同时潜在地改善患者的整体健康状况和治疗效果。